A model based assessment of redistribution dependent elimination and bioavailability pof rifabutin

Biopharmaceutics and Drug Disposition

Volumn 17, Issue 3, 1996, Pages 223-236

  Li, Ronald C ^a,b   Narang, Prem K ^a   Poggesi, Italo ^a   Strolin Benedetti, M ^a  

^a PFIZER INC   (United States)

^b and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

Author keywords

Redistribution; Rifabutin

Indexed keywords

DRUG METABOLITE; RIFABUTIN;

ADULT; ARTICLE; BIOAVAILABILITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; DRUG URINE LEVEL; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; VOLUNTEER;

ADMINISTRATION, ORAL; ADULT; ANTI-BACTERIAL AGENTS; HIV INFECTIONS; HUMANS; MALE; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; RIFABUTIN;

EID: 0029883102     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-081X(199604)17:3<223::AID-BDD954>3.0.CO;2-S     Document Type: Article

References (12)

1. C. D. Bruna, G. Schioppacassi, D. Ungheri, D. Jabes, E, Morvillo and A. Sanfilippo, LM 427, a new spiropiperidylrifamycin: in vitro and in vivo studies. J. Antibiot. (Tokyo), 36, 1502-1506 (1983).
2. L. B. Heifets, M. D. Iseman, P. J. Lindholm-Levy and W. Kanes, Determination of ansamycin MICs for Mycobacterium avium complex in liquid medium by radiometric and conventional methods. Antimicrob. Agents Chemother., 28, 570-575 (1985).
3. L. B. Heifets, P. J. Lindholm-Levy and M. A. Flory, Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis. Am. Rev. Respir. Dis., 141, 626-630 (1990).
4. M. H. Skinner, M. Hsieh, J. Torseth, D. Pauloin, G. Bhatia, S. Harkonen, T. C. Merigan and T. F. Blaschke, Pharmacokinetics of rifabutin. Antimicrob. Agents Chemother., 33, 1237-1241 (1989).
5. F. Oesch, M. Arand, M. Strolin-Benedetti, P. Dostert and M. G. Castelli, Inducing properties of rifabutin and rifampicin for selected drug metabolizing enzymes in female rat liver. IXth International Conference on AIDS, Berlin June 1993, Vol. 1, p. Abstract PO-B07-1155, 328.
6. M. Strolin-Benedetti, C. Efthymiopoulos, D. Sassella, E. Moro and M. Repetto, Autoinduction of rifabutin metabolism in man. Xenobiotica, 20, 1113-1119 (1990).
7. E. Perucca, R. Grimaldi, G. M. Frigo, A. Sardi, H. Monig and E. E. Ohnhaus, Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects. Eur. J. Clin. Pharmacol., 34, 595-599 (1988).
8. A. Akaike, Posterior probabilities for choosing a regression model. Ann. Inst. Math. Stat., 30, A9 (1978).
9. K., Yamaoka, T. Nakagawa and T. Uno, Application of Akaike information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J. Pharmacokinetic. Biopharm., 6, 165 (1978).
10. G. Acocella, V. Pagani, M. Marchetti, G. C. Baroni and F. B. Nicolis, Kinetic studies on rifampicin. Chemotherapy, 16, 356-370 (1971).
11. U. Loos, E. Musch, J. C. Jensen, G. Mikus, H. K. Schwabe and M. E. Eichelbaum, Pharmacokinetics of oral and intravenous rifamipicin during chronic administration. Klin. Wochenschr., 63, 1205-1211 (1985).
12. P. K. Narang, S. Gupta, R. C. Li, M. Strolin-Benedetti, C. Della Bruna and J. R. Bianchine, Assessing dosing implications of enzyme inducing potential: rifabutin (RIF) vs. rifampin (RFM). 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, October 1993, Abstract 598, p. 31.